Skip to main content
logo
Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
2.600
-0.220 (-7.80%)
Sep 1, 2026, 4:00 PM EDT - Market closed

Virax Biolabs Group Income Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
0.010.010.160.01-
Revenue Growth
96.23%-95.95%1727.11%-93.09%-
Cost of Revenue
00.060.110.01-
Gross Profit
0.01-0.050.05-0-
Selling, General & Admin
2.673.994.573.551.3
Research & Development
3.742.031.612.180.43
Operating Expenses
6.416.026.195.731.73
Operating Income
-6.4-6.08-6.14-5.73-1.73
Interest Expense
-0.06-0.06-0.03-0.02-0.02
Currency Exchange Gain (Loss)
0.53-0.090.03--
Other Non Operating Income (Expenses)
00.02-0.02-0-0
EBT Excluding Unusual Items
-5.93-6.2-6.15-5.75-1.75
Asset Writedown
---0.39--
Legal Settlements
---0.21--
Other Unusual Items
--0.010.29-
Pretax Income
-5.93-6.2-6.74-5.46-1.75
Income Tax Expense
-0.9-0.14---
Earnings From Continuing Operations
-5.03-6.07-6.74-5.46-1.75
Minority Interest in Earnings
0.010.010.0100.04
Net Income
-5.02-6.06-6.73-5.46-1.71
Net Income to Common
-5.02-6.06-6.73-5.46-1.71
Net Income Growth
-----
Shares Outstanding (Basic)
00000
Shares Outstanding (Diluted)
00000
Shares Change
166.46%85.92%88.76%11.15%-
EPS (Basic)
-12.64-40.62-83.90-128.35-44.67
EPS (Diluted)
-12.64-40.62-83.90-128.35-44.75
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-4.88-5.17-7.35-4.18-0.81
Free Cash Flow Per Share
-12.27-34.63-91.57-98.30-21.15
Gross Margin
61.90%-32.34%-15.94%-
Operating Margin
-51515.17%-95984.87%-3922.37%-66963.68%-
Profit Margin
-40439.11%-95739.17%-4304.81%-63748.32%-
Free Cash Flow Margin
-39263.65%-81621.64%-4698.55%-48823.35%-
EBITDA
-6.05-5.82-6.08--
D&A For EBITDA
0.350.260.05--
EBIT
-6.4-6.08-6.14-5.73-1.73
SEC Filings: 10-K · 10-Q